CD274 and neoplasm: Given the limited number of patients with durable responses to these treatments, research efforts have focused on better understanding those patients who are particularly amenable to ICB, and have discovered that numerous markers, such as tumor mutational burden and PD-L1 status, can be predictors of response in some cases (6–10).